Pegaptanib for wet macular degeneration

Keyphrases

• Pegaptanib 100%
• Wet Macular Degeneration 100%
• Age-related Macular Degeneration 80%
• Vascular Endothelial Growth Factor 80%
• Aptamer 80%
• Angiogenesis 40%
• VEGF165 40%
• United States 20%
• Vision Loss 20%
• Amino Acids 20%
• New Drugs 20%
• Vascular Permeability 20%
• Aqueous Solution 20%
• Surgical Treatment 20%
• Adverse Events 20%
• Macula 20%
• Neovascular 20%
• Developed Countries 20%
• Macular Degeneration 20%
• Macromolecules 20%
• Chemically Synthesized 20%
• New Blood Vessel 20%
• Pfizer 20%
• Molecular Structure 20%
• Secreted Proteins 20%
• PEGylated 20%
• Single-stranded nucleic Acid 20%
• Wet Age-related Macular Degeneration 20%
• Pegaptanib Sodium 20%
• Three-dimensional Configuration 20%
• Macugen 20%
• Neovascular Age-related Macular Degeneration (nAMD) 20%
• Severe Loss 20%
• Modified Oligonucleotides 20%
• Pathologic Angiogenesis 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Wet Macular Degeneration 100%
• Pegaptanib 100%
• Age Related Macular Degeneration 71%
• Aptamer 57%
• Vasculotropin 28%
• Visual Impairment 14%
• Adverse Event 14%
• Amino Acid 14%
• Nucleic Acid 14%
• Vasculotropin Receptor 14%
• Macular Degeneration 14%
• Vasculotropin Inhibitor 14%
• Oligonucleotide 14%